Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Transl Oncol ; 18(2): 189-95, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26250765

RESUMO

BACKGROUND: Response to chemotherapy is a prognostic factor in patients with Ewing sarcoma (ES); the role of FDG PET to predict response in these patients has not been thoroughly investigated. We evaluated the diagnostic accuracy and the potential of FDG PET to predict response to chemotherapy (CHT). MATERIALS AND METHODS: We analyzed data of 50 patients with ES (median age 12.6 years). All patients were treated with neoadjuvant CHT, and underwent surgery for local control. All patients had (18)F-FDG PET/CT at diagnosis and after induction CHT, prior to local control. We compared response assessed by histopathology with FDG PET using standard uptake values (SUVs). RESULTS: Median SUV at diagnosis (SUV I) was 5 (range 1.2-17), and median SUV after neoadjuvant chemotherapy (SUV II) was 1.8 (range 0-8.4). Median SUV II/I ratio was 0.3 (range 0-1). SUV at diagnosis was significantly lower in patients with good histological response than in patients with poor histological response (median 3.8 vs. 7.2, p 0.02). We found a significant correlation between SUV II and outcome; the positive predictive value of an SUV II ≤ 2.5 for favorable response was 84.21 %, and the median SUV II was significantly higher in patients with disease progression (2.3 vs. 1.6, p = 0.04). In multivariate analysis, necrosis and SUV II were significant predictors of outcome. CONCLUSIONS: (18)F-FDG PET demonstrates high diagnostic accuracy for response to initial chemotherapy in patients with ES and it correlates with outcome. The role of FDG PET in predicting response and outcome should be further investigated.


Assuntos
Neoplasias Ósseas/diagnóstico por imagem , Tomografia por Emissão de Pósitrons/métodos , Sarcoma de Ewing/diagnóstico por imagem , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/patologia , Criança , Pré-Escolar , Progressão da Doença , Feminino , Fluordesoxiglucose F18 , Humanos , Estimativa de Kaplan-Meier , Masculino , Imagem Multimodal , Prognóstico , Modelos de Riscos Proporcionais , Compostos Radiofarmacêuticos , Estudos Retrospectivos , Sarcoma de Ewing/tratamento farmacológico , Sarcoma de Ewing/patologia , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Adulto Jovem
2.
Med Wieku Rozwoj ; 5(3 Suppl 1): 7-13, 2001.
Artigo em Polonês | MEDLINE | ID: mdl-12004147

RESUMO

Nephrotoxicity is observed in 30% of patient's treated with chemotherapy schedules based on cisplatin analogues. Ethyol (amiphostin) was used as a protectant of kidney in 3 paediatric patients with neoplastic disease. Two patients suffered from Wilms tumour. One of them, a 5 month old boy presented with agenesis of the right kidney and stage II tumour in the left kidney. Bilateral Wilms tumour was recognised in a 6 year old girl. In both cases glomerular filtration was diminished. The third patient was a girl aged 5 who had isolated relapse of neuroblastoma in the central nervous system. Primary treatment caused nephrotoxic complications such as Fanconi syndrome and diminished glomerular filtration (66 ml/min). In these 3 cases Ethyol was used every lime before analogues of cisplatin were given. Tolerance and the effect of this protectant were good.


Assuntos
Amifostina/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Taxa de Filtração Glomerular/efeitos dos fármacos , Nefropatias/induzido quimicamente , Protetores contra Radiação/uso terapêutico , Neoplasias do Sistema Nervoso Central/tratamento farmacológico , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Nefropatias/fisiopatologia , Neoplasias Renais/tratamento farmacológico , Masculino , Neuroblastoma/tratamento farmacológico , Resultado do Tratamento , Tumor de Wilms/tratamento farmacológico
3.
Wiad Lek ; 51 Suppl 4: 338-41, 1998.
Artigo em Polonês | MEDLINE | ID: mdl-10731996

RESUMO

Triton's tumor is a rare neoplasm, consisting of both neurogenic and rhabdomyoblastic components. Triton's tumor does not respond well to chemo- or radiotherapy, resulting in its poor therapy effects. This paper reports on two cases of this malignancy diagnosed in our department. The first one was treated with CWS chemotherapy followed by radical tumor resection, which resulted in 4.5 year complete remission. The other patient was treated with chemotherapy according to CWS protocol, achieving partial regression of the tumor. We suggest that this response may be connected with the sensitivity of the RMS embryonal component of the tumor to chemotherapy. This partial remission may create a possibility of radical tumor resection.


Assuntos
Neurilemoma/diagnóstico , Pré-Escolar , Terapia Combinada , Feminino , Humanos , Lactente , Masculino , Neurilemoma/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...